John R. Drexel
IV: John R. Drexel IV (“Nick”) is the former Managing Director of Kidder,
Peabody & Co., Inc. and President and CEO of its subsidiary, Kidder Peabody
International Investments, Inc. At present, Mr. Drexel is a Co-Founder and
Managing Director of HD1, LLC. The firm focuses on providing consulting and
project management services to clients engaged in forestry, agriculture,
sustainable energy and K-12 education. In addition, Mr. Drexel is Chairman of
Sage 3, LLC, a family owned company providing investment and business services,
primarily to several (unrelated) family offices and charitable trusts. He also
serves on the Boards of several privately owned companies.
Previously, Mr. Drexel was President of
Concord International Investments, LP. His career in the financial services
industry began at Fiduciary Trust Co., Inc. where he was an Investment Officer.
Mr. Drexel also served on the staff of former Senator Claiborne Pell (D-RI) for
currently serves on the Boards of the Woods Hole Oceanographic Institute (an
Incorporator), The Pilgrims (Executive Committee and President of its
Foundation), The Atlantic Partnership (Director), The New Hudson Foundation
(Trustee), The Pave the Way Foundation (Director), The Order of St. John of
Jerusalem (as a Bailiff Grand Cross, and in its Priory in the US as Prior
Emeritus and Life Governor).
recently completed terms as a Trustee of Drexel University and the New Zealand
Government Trade and Industry (Advisory Board). He also has served the UN in
advisory capacities, including on the Advisory Boards of the UN School and
UNOPS (UN Office of Project Services) as well as the Business Advisory
Committee (based in New York City).
Dr. Michael Goldblatt:
Michael Goldblatt has played a central role in the invention, development and
application of several life science and technological innovations over the past
25 years. Among others milestones, he pioneered an in vitro fully-human immune
system, femto-second lasers, self-sterilizing packaging, nickel-zinc batteries,
meta-materials, therapeutic proteins, host-oriented therapeutics for emerging
and infectious disease, and optical computing technologies.
At present Dr.
Goldblatt is President and Chief Executive Officer of Functional Genetics, a
biopharmaceutical company. Dr. Goldblatt joined Functional Genetics, Inc. in
2003 after his appointment as Director of Defense Sciences at the Defense
Advanced Research Projects Agency (DARPA). Part of Dr. Goldblatt’s legacy
at DARPA is represented by his foundation to make biological research an
integral part of the Department of Defense. This included programmatic thrusts
in defending against biological threats, leveraging biology to enhance defense
systems and enhancing the human performance program.
Prior to his
work with the Department of Defense, Dr. Goldblatt was the Science and
Technology officer for McDonald's Corporation with broad responsibilities,
including nutrition, product development and food safety. Before joining
McDonald’s Corporation, Dr. Goldblatt was Director of Scientific and Regulatory
Affairs at General Foods Corporation.
holds a J.D., Ph.D. and M.S. from the University of California at Davis and a
B.A. in Biology from Reed College. Dr. Goldblatt is admitted to practice
law by the Washington, DC and U.S. Patent Bars.